Date: 2016-01-13
Type of information: R&D agreement
Compound: T cell receptor (TCR) product candidates
Company: Kite Pharma (USA - CA) Leiden University Medical Center (The Netherlands)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: R&D licensing
Action mechanism: cell therapy
Disease: solid tumors associated with human papillomavirus type 16 (HPV16) infection
Details: * On January 13, 2016, Kite Pharma announced that its European subsidiary has entered into a research and license agreement with Leiden University Medical Center (LUMC) to identify and develop T cell receptor (TCR) product candidates targeting solid tumors that are associated with the human papillomavirus (HPV) type 16 infection. Under the terms of the agreement, Kite Pharma EU will partner with the LUMC Department of Clinical Oncology and Professor Dr. Sjoerd van der Burg, a leader in the research of HPV-associated cancers. Kite will also receive an exclusive option to license multiple TCR gene sequences for the development and commercialization of product candidates. Kite Pharma EU, based in Amsterdam , is focused on the discovery and development of tumor-specific TCRs for broad use in cancer treatment based on its TCR-GENErator™ platform. Kite Pharma EU is comprised of a leading team of immuno-oncology researchers and collaborators, including Professor Dr. Ton N. M. Schumacher , who serves as Chief Scientific Officer.
Financial terms:
Latest news:
